About REPL

Founded: 2015
Employees: 479
CEO: Sushil Patel
WebsiteView website: www.replimune.com

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Recent REPL News & Updates

Announcement • Jun 02

+ 1 more update

Replimune Group Presents Three-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial of RP1 Plus Nivolumab in Patients with Anti-PD-1-Failed Melanoma

Replimune Group presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an oral session at the 2026 American Society of Clinical Oncology annual meeting. Oral Presentation: A 3-year landmark overall survival analysis of RP1 plus nivolumab in patients with anti-PD-1-failed melanoma from the IGNYTE clinical trial; Date/Time: May 30, 2026, 5:30 PM CDT; Location: E451; Abstract: 9518; Presenter: Michael Wong, MD, PhD. RP1 (vusolimogene oderparepvec) plus nivolumab achieved a median overall survival (mOS) of 32.9 months in patients with anti–PD-1–failed advanced melanoma, a population with limited treatment options. At 3 years, 47.8% of all treated patients remained alive, rising to 83.5% among responders, underscoring the depth and durability of the treatment's benefit. The objective response rate (ORR) was 33.6%, with a median duration of response (DOR) of 24.8 months; 44.8% of responders maintained their response at 3 years. Meaningful survival benefit was observed across all key patient subgroups, including those with varying disease stage, PD-L1 expression status, prior anti–CTLA-4 therapy, and primary or secondary anti–PD-1 resistance. The combination continued to demonstrate a favorable and manageable safety profile over long-term follow-up, with predominantly Grade 1–2 constitutional side effects, no Grade 5 events, and no new safety signals identified. RP1 (vusolimogene oderparepvec) is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response.

Recent updates

No updates

Replimune Group, Inc. Stock Price

REPL Share Price Performance

REPL Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Replimune Group, Inc. Key Details

About REPL

Recent REPL News & Updates

Replimune: Modeling The Coin Flip Of FDA Approval

Replimune Group Presents Three-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial of RP1 Plus Nivolumab in Patients with Anti-PD-1-Failed Melanoma

Recent updates

Replimune Group, Inc. Competitors

Arcus Biosciences

Dyne Therapeutics

IDEAYA Biosciences

Arcutis Biotherapeutics